Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Vectura Group PLC    VEC   GB00B01D1K48

VECTURA GROUP PLC

(VEC)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Vectura : Drugmaker Vectura parts ways with CEO Ward-Lilley

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/10/2019 | 03:20am EDT
FILE PHOTO: Vectura CEO James Ward-Lilley poses for a photograph in London

(Reuters) - British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.

Ward-Lilley, who has been in charge of the company since September 2015, will be replaced by Chief Financial Officer Paul Fry on an interim basis as the company starts looking for a new CEO, Vectura said.

"The Board and James have agreed that after four years as CEO it is now time for a new leader to take Vectura through its next phase of development," Vectura Chairman Bruno Angelici said.

Prior to taking on the role at Vectura, Ward-Lilley had worked for nearly three decades for pharmaceutical giant AstraZeneca.

The 54-year old led Vectura through its $621 million purchase of rival SkyePharma couple of years ago, but shares in the company have lost more than half their value under his management.

Vectura said last month that its outlook was in line with its guidance for the current year, after reporting a bigger operating loss for the last fiscal year in March partly due to costs relating to the discontinuation of a drug to treat severe asthma.

(Reporting by Muvija M in Bengaluru; Editing by Patrick Graham)

Stocks mentioned in the article
ChangeLast1st jan.
VALUE8 1.82% 5.6 Delayed Quote.18.14%
VECTURA GROUP PLC 0.00% 81 Delayed Quote.15.71%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VECTURA GROUP PLC
06/11VECTURA : announces leadership changes
AQ
06/11VECTURA : looking for new chief executive officer, with current incumbent, James..
AQ
06/10VECTURA : Drugmaker Vectura parts ways with CEO Ward-Lilley
RE
05/24Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM..
AQ
05/24VECTURA : Awarded $2.5 Million from Novartis After Drug Makes Regulatory Progres..
DJ
05/16VECTURA : data to be shared at ATS 2019
AQ
05/15VECTURA : Swisslog wins major order from Ikea in Malaysia
AQ
05/08VECTURA : Cheers patent case win versus gsk
AQ
05/06VECTURA : wins US GSK patent litigation and awarded $89.7m in damages by jury
AQ
05/04VECTURA : Wins US GSK Patent Litigation and Awarded $89.7Million in Damages by T..
BU
More news
Financials (GBP)
Sales 2019 161 M
EBIT 2019 29,6 M
Net income 2019 -16,4 M
Finance 2019 108 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 2,60x
EV / Sales 2020 2,33x
Capitalization 527 M
Chart VECTURA GROUP PLC
Duration : Period :
Vectura Group PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VECTURA GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 1,13  GBP
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
James Ward-Lilley Chief Executive Officer & Executive Director
Bruno Francois Jules Angelici Non-Executive Chairman
Anthony Fitzpatrick Executive Vice President-Operations
Fry Andrew Paul Chief Financial Officer & Executive Director
Gonzalo de Miquel Chief Medical Officer & Executive VP-Development
Sector and Competitors